But the results are contradictory; in a recent breast cancer clinical trial, the use of neutralizing anti-CSF1R and anti-CSF1 antibodies, along with the small-molecule inhibitors of CSF1R, showed an enhancement in the metastasis without altering primary tumor growth (58). The gene discussed is CSF1; the disease is breast cancer.